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Abstract
A proportion of classical Hodgkin lymphomas harbor the Epstein Barr virus (EBV). We previ-
ously demonstrated that associations between Human Leukocyte Antigen (HLA) alleles and
susceptibility to EBV+ classical Hodgkin lymphoma differ between European and Chinese
populations. Data on Hispanic populations is missing. Here we examined the association
between HLA type, tumor cell HLA expression and other characteristics in Hispanic Hodgkin
lymphoma patients. Hispanic Hodgkin lymphoma patients diagnosed at the Los Angeles
County-University of Southern California Medical Center from 2000–2012 were included
(n = 65). Formalin-fixed paraffin-embedded tumor tissue was analyzed for EBV by in situ
hybridization and for HLA class I and class II expression by immunohistochemistry. HLA typ-
ing was performed by HLA-A specific quantitative PCR of genomic DNA from tissue. Thirty
patients (46%) had EBV+ tumors. Expression of HLA class I (p = 0.0006) was significantly
associated with EBV+ tumor status in Hispanic patients, similar to Europeans and Chinese.
A positive association between HLA class II expression and EBV+ tumor status, as present
in large studies in Europeans, was not found (p = 0.06). The prevalences of the specific
European HLA-A*01 risk and European HLA-A*02 protective types were not significantly
associated with EBV+ tumors among these Hispanic patients, however numbers were too
low to draw firm conclusions. The HLA-A*02:07 allele, that is associated with EBV+ Hodgkin
lymphoma in Chinese, was absent. In conclusion, the association between EBV positivity in
tumor cells and HLA class I expression appears to be consistent across different popula-
tions. Larger studies in Hispanics are needed to evaluate HLA allele susceptibility
associations.
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Introduction
Classical Hodgkin lymphoma (cHL) is a malignant lymphoma of B cell origin defined by a
pathognomonic giant malignant cell, the Hodgkin Reed-Sternberg (HRS) cell. It comprises
11% of malignant lymphomas and is the most common lymphoma of young adults. cHL is a
unique malignancy as the majority of the tumor is composed of non-malignant cells surround-
ing the HRS cells [1].
Epidemiologically, cHL is composed of multiple disease subtypes with different risk pat-
terns based on age [2], histology [3], and Epstein Barr Virus (EBV) status [4–]. Age distribu-
tion in HL has three incidence peaks, a small peak in childhood, a sharply rising incidence
peak in adolescence and early adulthood (in developed countries), and a gradually increasing
incidence after 50 years. cHL can be divided into four histologic subtypes, consisting of nodu-
lar sclerosing (NS), mixed cellularity (MC), lymphocyte rich (LR) and lymphocyte depleted
(LD) [5].
Epstein-Barr Virus (EBV) has been shown to be clonally integrated in the malignant HRS
cells in about 40% of cHL patients overall and ~20% of young adult nodular sclerosis cases
(EBV+ cases) [1]. Prevalence of EBV involvement varies across age, sex, ethnicity and geo-
graphic location [6]. Latent EBV infection has B cell transforming potential and occurs early in
the development of cHL, prior to clonal expansion of the malignant cells [7]. EBV infection in
cHL involves a specific pattern of so-called latency type II viral protein production, limited to
latent membrane protein 1 (LMP1), latent membrane protein 2 (LMP2) and EBV nuclear anti-
gen 1 (EBNA) [8]. The presentation of peptides derived from these EBV proteins is mediated
through human leukocyte antigens (HLA) classes I and/or II. Both cytotoxic T cells that recog-
nize HLA class I [9,10] and T helper cells that react to HLA class II are involved in the anti-
tumor immune response against EBV [11]. Genetic studies screening the entire HLA region
and subsequent targeted studies have identified a clear role for the HLA-A gene in susceptibil-
ity to EBV+ cHL [12,13]. More specifically regarding HLA class I subgroups, the HLA-A01
subtype of HLA I is positively associated with EBV+ cHL while the HLA-A02 subtype is nega-
tively associated with EBV+ cHL [14]. More recently, GWAS studies have shown that the
HLA-A gene region is the dominant genetic susceptibility risk factor for EBV+ cHL, while loci
in the class II region (HLA-DRA) are associated with EBV- cHL and NS cHL [15–17].
In multiple European studies, expression of HLA I and II on the cell surface of HRS cells is
associated with EBV+ disease, suggesting that antigen presentation of EBV-derived peptides
can occur in these tumor cells [18–20]. Both CD4 and CD8 T cells are in the close vicinity of
the HRS cells and can presumably be activated by antigen presentation. In contrast, HLA class
I and/or class II is downregulated in the HRS cells in many EBV- cHL cases in Western Europe
[18–20].
In a study of Chinese cHL patients, HLA class I expression was positively associated with
EBV status; whereas HLA class II was not [21]. HLA-typing of these Chinese patients showed
that the HLA-A02 type (which includes amongst others HLA-A02:01 and HLA-A02:07)
was not associated with EBV+ cHL. This is explained by differential susceptibility effects of the
specific HLA-A02 suballeles. The European protective allele HLA-A02:01 that accounts for
the A02 protective effect in Europeans is uncommon in Chinese and showed a trend for
being protective. However, the more common Chinese-specific subtype HLA-A02:07 was
strongly associated with the risk of EBV+ cHL. Interestingly, the same allele proved to be pro-
tective for developing EBV- cHL in the Chinese [22]. Thus, differential genetic susceptibility
across populations contribute to the well-known differences in incidence of EBV+ cHL in vari-
ous parts of the world.
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Hispanics (mostly of Mexican descent) comprise the largest non-white ethnic group in Los
Angeles County [23]. California Hispanic cHL patients have a distinct disease pattern with a
higher proportion of EBV+ and MC subtypes compared to non-Hispanic whites, and the
HLA-A01 frequency is intermediate (7% in Hispanics, 17% in non-Hispanic whites) [24].
Therefore, we examined HLA class I and II expression in relation to EBV status, the suscepti-
bility effects of HLA-A01 and A02 (including A02:01 and A02:07) and other characteristics
in a Hispanic population diagnosed at a large county hospital in Los Angeles County.
Materials and methods
Patients and tumors
Sixty-five Hispanic cHL patients of Mexican descent diagnosed at the Los Angeles County-
University of Southern California (LAC-USC) Medical Center from 2000–2012 with sufficient
tumor biopsy tissue were identified. Formalin-fixed paraffin-embedded tumor blocks were
reviewed by a pathologist and areas marked for coring meeting the following criteria: sufficient
amount of tumor, minimal sclerosis and presence of a minimum number of HRS cells (at least
3 present). Three 0.6mm cores were extracted from these areas in each block and used in tissue
microarrays (TMAs).
Patient characteristics
Pathology reports and patient charts from LAC-USC were reviewed and information on eth-
nicity, age at diagnosis, sex, histological subtype and birthplace were abstracted. The study was
approved by the University of Southern California Institutional Review Board in accordance
with the 1964 Declaration of Helsinki. There was no patient contact in this study; medical rec-
ords and tumor blocks were linked and coded with numeric identification numbers. The indi-
vidual patient data was stored on a separate password-protected server available only to key
personnel and the personal identifiers necessary for linking the chart information to the
tumors during the study period have now been removed, making the study anonymous.
Immunohistochemistry
Five μm tissue slides were sectioned on APES coated slides, and deparaffinized utilizing xylene
(2x10min) and ethanol (2x5min). The slides were rinsed with PBS before blocking with 0.3%
H2O2 for 30 min. In-situ hybridization for EBV encoded RNA (EBER) was performed with
the Novocastra™ Epstein-Barr virus ISH Kit using standard methods [14]. Monoclonal anti-
bodies to the HLA-class I heavy chain (HC-10, kindly provided by prof. dr. J. Neefjes, the
Netherlands Cancer Institute, Amsterdam, the Netherlands) and polyclonal rabbit anti human
B2 microglobulin (B2M, DAKO, Glostrup, Denmark), at dilutions of 1:500 and 1:400 respec-
tively, were used to mark HLA class I expression. Monoclonal antibody to CR3/43 (DAKO)
that binds to the HLA-II chain of HLA-DP, HLA-DQ, and HLA-DR at a dilution of 1:200 was
used to mark HLA class II expression. CD30 was used to aid in identifying HRS cells. Tissues
were stained using the Leica Bond 3 staining platform. Scoring for EBER and HLA expression
was performed if at least 50 HRS cells were present in all three cores combined. A case was
considered positive for HLA if there was membranous staining in more than 50% of the HRS
cells.
HLA-A*01/A*02 quantitative PCR
Genomic (g) DNA was isolated from cHL FFPE tissue sections using ReliaPrep™ FFPE gDNA
Miniprep System (Promega Corporation, Madison, USA) according to the manufacturer’s
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protocol. DNA concentration was measured with a Nanodrop™ 1000 Spectrophotometer
(Thermo Fisher Scientific Inc., Waltham, USA). gDNA samples were diluted to a concentra-
tion of 4ng/μl for quantitative (q) PCR analysis.
qPCR analysis was performed in triplicate on an ABI PRISM 7900HT (Applied Biosys-
tems™, Foster City, USA) with SYBR Green in a 384-well microtiter plate using primers for
HLA-A01 and HLA-A02 (Table 1). Primers specific for the PTP4A1 gene were used as a
quality and quantity control. Primer concentrations used for the reaction were as follows, 2μM
for GP405, 1.5μM for GP406 and 3μM for the HLA-A02 primers and the PTP4A1 primers.
All reactions were performed in a final volume of 10μl consisting of 5μl SYBR1 Green PCR
Master Mix (Applied Biosystems™), 1μl of each primer, 0.5μl of milliQ and 2.5μl of gDNA
(4ng/μl). qPCR cycling conditions consisted of an initial 2 min. AmpErase UNG activation
step at 50˚C and a 10 min. hot start at 95˚C followed by 40 cycles of denaturation at 95˚C for
15s and combined annealing/extension at 60˚C for 1 minute. A melt analysis was generated
(95˚C for 15s, 60˚C for 15s and 95˚C for 15s) to verify specificity of the PCR products. Each
qPCR included no template controls (NTC) and 16 reference samples with known HLA-A
genotype.
Mean cycle threshold (Ct) values for all genes were quantified by the SDS software (version
2.2). Samples with poor DNA quality were excluded based on a Ct value higher than 36 for
PTP4A1. Relative expression levels were calculated as 2-ΔCt. Based on the 16 HLA-A typed
samples, cut-off levels for HLA-A01 positivity was set at a 2-ΔCt value of 0.03 and for
HLA-A02 at a 2-ΔCt of 0.1. To indicate the absence of HLA-A02 or HLA-A02 cut-off levels
were set at a 2-ΔCt value of 0.015 or 0.05 respectively.
Subtyping of HLA-A02 positive individuals was performed by amplification and sequence
analysis of exon 2 and exon 3 regions that contain a number of SNPs that discriminate between
the common and well-documented (CWD) allelic variants in the Hispanic population [22].
Statistical analysis
Associations between HRS cell HLA expression (Class I and Class II), HRS cell EBV status
(positive [+] or negative [–]), histology (nodular sclerosis [NS] vs. other) and demographics
(age, sex, birthplace) were evaluated using a Pearson Chi square test or Fisher’s exact test for
expected cell counts < 5. A logistic regression analysis was conducted to assess the associations
between HLA class I and class II expression and all characteristics using the Firth penalized
likelihood approach to account for small sample size. Because HRS cell EBV status is associated
with histological subtype, we adjusted for histology (NS vs. other) in the logistic regression
analyses. Prevalence of the specific HLA Class I alleles HLA-A01 and HLA-A02 were com-
pared between EBV+ and EBV- subgroups by Pearson Chi square and Fisher’s exact tests. For
Table 1. Primers used for the HLA-A*01 and HLA-*02 quantitative PCR.
Specificity Primer Sequence* (5’–3’) Location Size
HLA-A*01 GP405 F:TCCGCGGGTACCGGCAGGAC Exon 3 164bp
GP406 R:GCACCGGCCCTCCAGGTAGA Exon 3
HLA-A*02 GP343 F:GAGCCCCGCTTCATCGCA Exon 2 132bp
GP344 R:CCCGTCCCAATACTCCGGA Exon 2
PTP4A1 PTP4A1F F:GCACAGCACGACCTCTATGC Exon 2 142bp
PTP4A1R R:CCAGGTCAGAACTCTTGTAAAATGC Exon 2
Note:
*F: forward primer, R: reverse primer
https://doi.org/10.1371/journal.pone.0174457.t001
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these analyses, the outcome was EBV tumor status and the exposure the specific germline
HLA allele. All significance tests were two-sided and the significance level (α) was 0.05. In
addition, we performed a power analysis to see whether we would have enough samples to
find associations between HLA expression and HRS cell EBV status similar to the European
population [20,25]. For HLA class I there was 99.8% power, for HLA class II this was only
29.8%. Analyses were performed with SPSS and SAS.
Results
Population characteristics
Population and tumor characteristics are shown in Table 2 and S1 Datatable. Of the 65 His-
panic patients, 47 (72.3%) were born outside the U.S. Thirty (46%) had EBV+ tumors. Histo-
logically, 40 patients (61.5%) had NS, 19 (29.2%) had MC, 5(7.7%) had LD, and 1 (1.5%) had
LR. There were more male (n = 47; 72.3%) than female (n = 18; 27.7%) patients.
HLA expression and EBV association
Of the 65 cases, definitive HLA class I and HLA class II expression results were obtained for 50
and 44 patients’ tumors, respectively. HLA class I expression was positively associated with
EBV+ cHL (p = 0.0006) (Table 3). There was no significant association between HLA class II
expression and EBV+ cHL (p = 0.06) (Table 3). In a logistic analysis, EBV+ tumor cell status
was significantly associated with HLA class I expression when adjusting for histology (Table 4,
OR = 6.53, 95%CI = 1.80–23.72). EBV+ tumor cell status was not significantly associated with
HLA class II expression (OR = 4.87, 95% CI = 0.75–31.69). HLA expression was not associated
with any demographic characteristics. Relative to other histological subtypes, NS was not sig-
nificantly associated with HLA class I (p = 0.08), or HLA class II (p = 0.7) expression (Table 3).








• Female 18 (27.7)
• Male 47 (72.3)
Birthplace
• US born 17 (26.1)
• Not US born 47 (72.3)
• Missing 1 (1.6)
EBV Tumor Status
• EBV- 35 (53.8)
• EBV+ 30 (46.2)
Histology
• Nodular sclerosis 40 (61.5)
• Mixed cellularity 20 (30.8)
• Lymphocyte depleted 4 (6.2)
• Lymphocyte rich 1 (1.5)
https://doi.org/10.1371/journal.pone.0174457.t002
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Results were unchanged when the analysis was adjusted for EBV tumor status (data not
shown).
Specific HLA-A allele associations
We observed no association between HLA-A01 or HLA-A02 types and susceptibility to
EBV+ cHL (Table 5, S1 Datatable). There was no association with expression of HLA class I
(Table 3). All 19 HLA-A02 positive patients carried the HLA-A02:01 allele. Two patients
Table 3. Association between HLA class I or II expression in Hodgkin Reed Sternberg cells and presence of Epstein-Barr Virus (EBV), Nodular
Sclerosis (NS) histology, birthplace, sex and HLA type in Hispanic classical Hodgkin lymphoma patients.
HLA class I P HLA class II P
Negative Positive Negative Positive
Sex
• Female 8 (32%) 5 (20%) 0.33 1 (11%) 10 (28%) 0.41a
• Male 17 (68%) 20 (80%) 8 (89%) 25 (71%)
Age (median) 27 37 0.65b 28 27 0.66b
Birthplace
• Foreign born 17 (68%) 19 (79%) 0.38 6 (67%) 25 (71%) 0.78
• US born 8 (32%) 5 (21%) 3 (33%) 10 (29%)
EBV
• EBV- 20 (80%) 8 (32%) 0.0006 8 (89%) 18 (51%) 0.06a
• EBV+ 5 (20%) 17 (68%) 1 (11%) 17 (49%)
Histology
• Non-NS 6 (24%) 12 (48%) 0.08 2 (22%) 13 (37%) 0.7a
• NS 19 (76%) 13 (52%) 7 (78%) 22 (63%)
HLA-A*01
• HLA-A*01- 20 (87%) 23 (92%) 0.66a 8 (89%) 29 (88%) 1a
• HLA-A*01+ 3 (13%) 2 (8%) 1 (11%) 4 (12%)
HLA-A*02
• HLA-A*02- 18 (78%) 14 (58%) 0.14 6 (67%) 24 (75%) 0.68a
• HLA-A*02+ 5 (22%) 10 (42%) 3 (33%) 8 (25%)
ap-value based on Fisher’s Exact test with two-sided alpha level of 0.05
bMann Whitney U test.
All other p-values are based on Pearson Chi-squared tests.
https://doi.org/10.1371/journal.pone.0174457.t003
Table 4. The association between EBV tumor status and HLA class I or HLA class II expression in Hispanic classical Hodgkin lymphoma patients.
EBV HLA expression ORunadja 95% CI ORadjb 95% CIb
Negative Positive
HLA class I
• EBV- 20 8 1.0 2.15–27.42 1.0 1.80–23.72
• EBV+ 5 17 7.67 6.53
HLA class II
• EBV- 8 18 1.0 0.8–35.93 1.0 0.75–31.69
• EBV+ 1 17 5.36 4.87
a Odds ratios estimated from logistic regression with Firth penalized likelihood approach
b Adjusted for histology (Nodular Sclerosis vs. others).
https://doi.org/10.1371/journal.pone.0174457.t004
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carried a second HLA-A02 suballele, one with A02:02 and the other with A02:06. The
HLA-A02:07 suballele was not present. Thus, in this study neither HLA-A02 nor any specific
HLA-A02 suballele was associated with EBV+ cHL.
Discussion
This study is the first to examine associations between HLA and tumor cell EBV status in a
Hispanic cHL population. Similar to previous studies in European and Chinese populations,
HLA class I expression was strongly associated with EBV+ cHL. HLA class I expression by
HRS tumor cells is quite consistent in European, Chinese and Hispanic cHL patients with per-
centages of 71%, 79% and 77% positivity in EBV+ and percentages of 14%, 30% and 29% posi-
tivity in EBV- tumors respectively [21,25]. It should be noted that scoring of membranous
HLA class I expression in HRS cells is somewhat challenging as all nucleated cells normally
express HLA class I. It helps to find areas in which tumor cells are adjacent, and in EBV+ cHL
the expression in HRS cells is usually stronger than in surrounding reactive infiltrating cells.
Nonetheless, we were able to reliably determine HLA class I expression in 50 out of the 65
patients.
Lack of membranous HLA class I has been attributed to mutations in beta-2-microglobulin
(B2M) which prevents formation of the HLA class I heavy chain-B2M complex in HRS cells
[26,27]. The high prevalence of HLA class I expression by EBV+ HRS cells in comparison to
EBV- HRS cells is counterintuitive, as this implies that anti-EBV cytotoxic immune responses
should be able to eradicate the tumor cells. On the other hand, retention of HLA class I expres-
sion may help the tumor cells in escaping from NK-cell mediated lysis [25]. In addition, HRS
cells are well known for exhibiting various other immunomodulating mechanisms, like pro-
duction of immunosuppressive cytokines, expression of PDL-1 and attraction of Th2 type T
cells that can inhibit cytotoxic responses [1].
The protective effect of the HLA-A02:01 allele in Europeans could be explained by com-
mon anti-EBV immune responses to antigens that are specifically presented by A02:01
encoded HLA [28]. At the moment, it is unknown how HLA-A01:01 and HLA-A02:07 exert
a risk effect, although this can be partially explained by lack of EBV latency type II responses in
the context of these alleles. The risk effect of HLA-A02:07 in Chinese EBV+ cHL patients
coincides with an increased risk for another EBV latency type II driven cancer, undifferenti-
ated nasopharyngeal carcinoma [29].
In the current study in Hispanics, we did not find a significant risk effect of HLA-A01 or
HLA-A02:07 nor a significant protective effect of HLA-A02 for EBV+ cHL. This might be
explained by the relatively low frequency of A01 and A02 and the absence of A02:07 in the




• HLA-A*01- 31 (91%) 22 (81%)
• HLA-A*01+ 3 (9%) 5 (19%) 0.44a
HLA-A*02
• HLA-A*02- 24 (71%) 18 (67%)
• HLA-A*02+ 10 (29%) 9 (33%) 0.74b
ap-value based on Fisher’s Exact test with two-sided alpha level of 0.05
bp-value based on Pearson Chi-squared test
https://doi.org/10.1371/journal.pone.0174457.t005
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Hispanic population. Indeed, given the measured allele frequencies in our Hispanic cohort,
there is only about 50% power to detect the A01 and the A02 associations as found in the
European population. Since we only interrogated the known risk and protective HLA-A alleles,
it is possible that other HLA genes or suballeles are involved in susceptibility to EBV+ cHL in
this population.
In comparison to HLA class I, HLA class II expression by tumor cells is somewhat more
variable with 70%, 52%, 94% expression in EBV+ and 53%, 43%, 69% in EBV- tumors in Euro-
peans, Chinese and Hispanics, respectively [20,21]. Although the HLA class II expression dif-
ferences between EBV+ and EBV- cHL are not very pronounced, they do show a similar trend
in all three populations and are significant in Europeans. Expression of HLA class II may be
involved in establishment of the CD4+ T cell infiltrate in the cHL tumor microenvironment,
however this is difficult to assess as it probably occurs early in disease pathogenesis [30]. Inter-
estingly, HLA class II associations are mainly associated with EBV- cHL [15–17,31].
In conclusion, our data demonstrate that EBV+ cHL tumor cells more frequently retain
HLA class I expression, regardless of ethnicity. Together with our previous studies, this study
emphasizes that differences in ancestry should be considered in HLA susceptibility studies in
cHL.
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